Private Asset Management Raised Its Gilead Sciences (GILD) Stake; 9 Bullish Analysts Covering Direct Line Insurance Group PLC (LON:DLG)

Private Asset Management Inc increased Gilead Sciences Inc. (GILD) stake by 19.82% reported in 2017Q3 SEC filing. Private Asset Management Inc acquired 23,555 shares as Gilead Sciences Inc. (GILD)’s stock declined 8.05%. The Private Asset Management Inc holds 142,405 shares with $11.54M value, up from 118,850 last quarter. Gilead Sciences Inc. now has $103.22 billion valuation. The stock decreased 0.05% or $0.04 during the last trading session, reaching $79.02. About 6.37M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since January 14, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.

Among 19 analysts covering Direct Line Insurance Group PLC (LON:DLG), 9 have Buy rating, 1 Sell and 9 Hold. Therefore 47% are positive. Direct Line Insurance Group PLC had 172 analyst reports since July 27, 2015 according to SRatingsIntel. Peel Hunt maintained it with “Hold” rating and GBX 365 target in Friday, January 27 report. The stock has “Hold” rating by Peel Hunt on Friday, August 4. The firm has “Neutral” rating by UBS given on Wednesday, November 4. The firm earned “Hold” rating on Monday, April 18 by Peel Hunt. The stock of Direct Line Insurance Group PLC (LON:DLG) has “Overweight” rating given on Wednesday, September 23 by JP Morgan. The rating was maintained by Goldman Sachs with “Neutral” on Wednesday, January 25. Barclays Capital maintained the stock with “Equal Weight” rating in Wednesday, September 14 report. The company was maintained on Tuesday, February 28 by Barclays Capital. The rating was maintained by Goldman Sachs on Friday, December 11 with “Neutral”. The rating was maintained by Deutsche Bank with “Buy” on Tuesday, October 24. See Direct Line Insurance Group PLC (LON:DLG) latest ratings:

05/01/2018 Broker: JP Morgan Rating: Overweight Old Target: GBX 450.00 New Target: GBX 450.00 Maintain
19/12/2017 Broker: Deutsche Bank Rating: Buy Maintain
11/12/2017 Broker: Barclays Capital Rating: Equal Weight Old Target: GBX 359.00 New Target: GBX 358.00 Maintain
23/11/2017 Broker: HSBC Rating: Buy Old Target: GBX 440.00 New Target: GBX 440.00 Maintain
16/11/2017 Broker: JP Morgan Rating: Overweight Maintain
10/11/2017 Broker: Deutsche Bank Rating: Buy Old Target: GBX 440.00 New Target: GBX 440.00 Maintain
09/11/2017 Broker: HSBC Rating: Buy Maintain
08/11/2017 Broker: Deutsche Bank Rating: Buy Old Target: GBX 440.00 New Target: GBX 440.00 Maintain
08/11/2017 Broker: JP Morgan Rating: Overweight Old Target: GBX 450.00 New Target: GBX 450.00 Maintain
07/11/2017 Broker: Shore Capital Rating: Sell Maintain

Investors sentiment increased to 1.03 in Q3 2017. Its up 0.10, from 0.93 in 2017Q2. It increased, as 96 investors sold GILD shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported. Hollencrest Secs Ltd Liability owns 9,023 shares or 0.1% of their US portfolio. The Sweden-based Healthinvest Ptnrs Ab has invested 7.25% in Gilead Sciences, Inc. (NASDAQ:GILD). Mirae Asset Investments Limited stated it has 0.18% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Rand Wealth Limited Co invested 0.16% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Moreover, Invest House Limited Liability Corporation has 0.75% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Wells Fargo & Company Mn owns 11.56M shares. Prudential Public Limited Com reported 0.81% stake. Regal Inv Advsr Lc reported 2,945 shares or 0.06% of all its holdings. North Point Port Managers Oh accumulated 202,405 shares or 2.77% of the stock. Tnb Financial stated it has 0.05% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Focused Wealth Management Inc holds 0.67% in Gilead Sciences, Inc. (NASDAQ:GILD) or 24,968 shares. Hanson Doremus Inv Mngmt has invested 0.05% in Gilead Sciences, Inc. (NASDAQ:GILD). Loomis Sayles And LP stated it has 0% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Cibc World Mkts stated it has 646,783 shares. Neville Rodie & Shaw reported 40,981 shares.

Private Asset Management Inc decreased Pfizer Inc (NYSE:PFE) stake by 15,467 shares to 501,352 valued at $17.90 million in 2017Q3. It also reduced Walt Disney Company (NYSE:DIS) stake by 4,685 shares and now owns 99,014 shares. Oracle Corporation (NYSE:ORCL) was reduced too.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 18 have Buy rating, 0 Sell and 12 Hold. Therefore 60% are positive. Gilead Sciences has $137 highest and $7200 lowest target. $97.04’s average target is 22.80% above currents $79.02 stock price. Gilead Sciences had 111 analyst reports since July 29, 2015 according to SRatingsIntel. As per Thursday, September 22, the company rating was initiated by Berenberg. The firm earned “Hold” rating on Thursday, December 21 by Oppenheimer. As per Friday, January 15, the company rating was upgraded by Bank of America. The rating was maintained by Credit Suisse with “Outperform” on Wednesday, March 23. Jefferies initiated the stock with “Hold” rating in Wednesday, September 9 report. The firm has “Equal-Weight” rating by Morgan Stanley given on Friday, October 2. RBC Capital Markets maintained it with “Outperform” rating and $90 target in Wednesday, November 2 report. The firm has “Outperform” rating by Credit Suisse given on Wednesday, September 14. The firm has “Hold” rating given on Wednesday, January 3 by Credit Suisse. RBC Capital Markets maintained it with “Outperform” rating and $95 target in Monday, October 3 report.

Since August 1, 2017, it had 0 insider buys, and 11 sales for $41.13 million activity. The insider MARTIN JOHN C sold $3.68M. Alton Gregg H had sold 50,000 shares worth $3.95M on Wednesday, August 30. Washington Robin L also sold $4.40 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Thursday, September 7. Meyers James R sold $4.99 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Thursday, August 31.